Loading...
Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma
BACKGROUND: Dimethyl fumarate (DMF), an oral agent approved for the treatment of relapsing–remitting multiple sclerosis (RRMS), has promising preclinical activity against glioblastoma (GBM). This phase I study sought to determine the recommended phase 2 dose (RP2D) of DMF and evaluate its safety and...
Na minha lista:
| Udgivet i: | Neurooncol Adv |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7212848/ https://ncbi.nlm.nih.gov/pubmed/32642720 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz052 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|